Neurogene Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NGNE | NGEN | RGNX | ALEC | VYGR | TSHA | |
|---|---|---|---|---|---|---|
| Market cap | 551.91M | 145.16M | 508.96M | 254.58M | 115.23M | 1.42B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.8 | -4.0 | -2.6 | -3.1 | -1.5 | -9.4 |
| Price/book | 2.0 | 4.3 | 5.8 | -25.6 | 0.7 | 3.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −3.79% | −44.30% | −34.28% | +63.35% | −57.14% | +1.49% |
| Today | +3.41% | +2.27% | +1.05% | +11.22% | +2.19% | +6.60% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NGNE news ›Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
New data showing rapid and durable full-length MECP2 expression in vivo with single-stranded AAV support improvements observed in NGN-401 Phase 1/2 trial New in vivo data demonstrate that miRNA-based auto-regulatory technology is not…
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional…
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
Adapted from iStock, zizar2002 Patients with Rett syndrome have historically had few treatment options—but 2027 could change that. Two gene therapies are at the FDA’s doorstep with strong data showing they can alter the trajectory of the…
Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)
Posted by Tristan Rich on Oct 24th, 2026 Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) and Neurogene (NASDAQ:NGNE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
More from 1 other outlet
Neurogene Inc. (NASDAQ:NGNE) Stock Has Average Target Price of $80.29 According to Brokerages
Posted by Defense World Staff on Oct 24th, 2026 View Our Latest Stock Analysis on Neurogene Shares of NASDAQ:NGNE opened at $23.55 on Wednesday. The stock’s 50-day moving average is $31.76 and its 200 day moving average is $31.09.…
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call
Investing News Network Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch RTX…
Neurocrine Biosciences: JPMorgan reports 5.2% stake
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) Stock Titan - [SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure Neurocrine Biosciences: JPMorgan reports 5.2% stake Neurocrine Biosciences,…
Neurocrine Biosciences, Inc. $NBIX Stock: Ninety One UK Ltd Increases Stake
Ninety One UK Ltd boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 160,372.7% during the 3rd quarter, Holdings Channel reports. The firm owned 434,881 shares of the company’s stock after buying an additional…
Prudential Financial Inc. Opens New Position in Neurogene Inc. (NGNE) With 2.23 Million Share Purchase
GuruFocus Prudential Financial Inc. Opens New Position in Neurogene Inc. (NGNE) With 2.23 Million Share Purchase Prudential Financial Inc.: A Global Investment Powerhouse Prudential Financial Inc
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- theglobeandmail.com12
- stocktitan.net7
- defenseworld.net2
- gurufocus.com2
- prnewswire.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.